Objective: To evaluate the prevalence of attention-deficit/hyperactivity disorder (ADHD), comorbidity rates with disruptive behavior disorders and main negative outcomes in primary school students in Nampula, Mozambique. Methods: We selected a random sample of 748 students for ADHD screening from a population of around 43,000 primary school students. The Swanson, Nolan, and Pelham Rating Scale version IV was applied to both parents and teachers. All students who screened positive (n=76) and a propensity score-matched random subset of students who screened negative (n=76) were assessed by a child psychiatrist. Results: The prevalence of ADHD was estimated at 13.4% (95%CI 11.5-19.2), and 30.6% of those with ADHD presented comorbid disruptive behavior disorders. Students with ADHD (n=36) had significantly higher rates of both substance use (alcohol, marijuana) (p < 0.001), and school failures than controls (n=96; p < 0.001). Comorbidity between ADHD and disruptive behavior disorders increased the chance of substance use (p < 0.001). Secondary analyses with more restrictive ADHD diagnostic criteria revealed a lower prevalence rate (6.7%; 95%CI 5.2-12.9) with similar patterns of associated factors and negative outcomes. Conclusion: Our findings demonstrated that ADHD is a prevalent mental disorder in Mozambique, and it is associated with similar comorbid profiles, predisposing factors, and negative outcomes, as in other cultures. Objective attentiondeficit/hyperactivity attentiondeficithyperactivity attention deficit/hyperactivity deficit hyperactivity ADHD, , (ADHD) Nampula Mozambique Methods 74 43000 43 000 43,00 Swanson Nolan teachers n=76 n76 n 76 (n=76 scorematched score matched psychiatrist Results 134 13 4 13.4 95CI CI 95 11.519.2, 115192 11.5 19.2 11 5 19 2 11.5-19.2) 306 30 6 30.6 n=36 n36 36 (n=36 alcohol, alcohol (alcohol marijuana 0.001, 0001 0.001 0 001 0.001) n=96 n96 96 (n=96 0.001. . 6.7% 67 7 (6.7% 5.212.9 52129 5.2 12.9 12 9 5.2-12.9 Conclusion profiles cultures attentiondeficit deficithyperactivity (ADHD 4300 00 43,0 n=7 n7 (n=7 1 13. 519 11.519.2 11519 115 11. 192 19. 11.5-19.2 3 30. n=3 n3 (n=3 0.00 n=9 n9 (n=9 6.7 (6.7 212 5.212. 5212 52 5. 129 12. 5.2-12. 430 43, n= (n= 51 11.519. 1151 11.5-19. 0.0 6. (6. 21 5.212 521 5.2-12 (n 11.519 11.5-19 0. (6 5.21 5.2-1 11.51 11.5-1 ( 5.2- 11.5-

ABSTRACT Background: The venom of Phoneutria nigriventer spider is a source of numerous bioactive substances, including some toxins active in insects. An example is PnTx4(5-5) that shows a high insecticidal activity and no apparent toxicity to mice, although it inhibited NMDA-evoked currents in rat hippocampal neurons. In this work the analgesic activity of PnTx4(5-5) (renamed Γ-ctenitoxin-Pn1a) was investigated. Methods: The antinociceptive activity was evaluated using the paw pressure test in rats, after hyperalgesia induction with intraplantar injection of carrageenan or prostaglandin E2 (PGE2). Results: PnTx4(5-5), subcutaneously injected, was able to reduce the hyperalgesia induced by PGE2 in rat paw, demonstrating a systemic effect. PnTx4(5-5) administered in the plantar surface of the paw caused a peripheral and dose-dependent antinociceptive effect on hyperalgesia induced by carrageenan or PGE2. The hyperalgesic effect observed in these two pain models was completely reversed with 5 µg of PnTx4(5-5). Intraplantar administration of L-glutamate induced hyperalgesic effect that was significantly reverted by 5 μg of PnTx4(5-5) injection in rat paw. Conclusion: The antinociceptive effect for PnTx4(5-5) was demonstrated against different rat pain models, i.e. induced by PGE2, carrageenan or glutamate. We suggest that the antinociceptive effect of PnTx4(5-5) may be related to an inhibitory activity on the glutamatergic system.

Resumo O objetivo deste trabalho foi testar a viabilidade da utilização da via vaginal em fêmeas bovinas visando à aplicação de ocitocina a partir de formulações específicas. A ocitocina foi utilizada associada a facilitadores de absorção e na forma injetável (para comparação). Foram produzidas sete formulações, todas com concentração de 5 UI/mL de ocitocina. O delineamento experimental foi em quadrado latino 8x8 (oito dias, oito tratamentos e oito novilhas ciclando). As administrações de ocitocina foram pela via vaginal e a ocitocina injetável pela via endovenosa, contendo 10 UI cada. Amostras de sangue (n=7) foram coletadas de cada animal, no tempo 0, anterior à administração dos tratamentos, e de três em três minutos até 18 minutos. A ocitocina foi extraída do plasma utilizando coluna cromatográfica C-18 e dosada utilizando o kit comercial Oxytocin EIA. Os resultados obtidos foram avaliados por análise estatística não paramétrica utilizando o teste Kruskal Wallis para comparação das médias. A concentração de ocitocina diferiu entre o tempo 0 e o tempo 12 minutos (p<0,05) para a formulação ocitocina em glicerina. Concluiu-se que houve absorção através da via vaginal para essa formulação. Mais estudos serão necessários para seu emprego no manejo com as fêmeas bovinas de forma efetiva.

Abstract The aim of this study was to test the feasibility of vaginal route in order to apply oxytocin in female bovines using specific formulations. The oxytocin was used in its injectable form (as a comparison standard) and associated with absorption enhancers. Seven formulations containing 5 IU/ml of oxytocin each were used. The experimental design was an 8x8 latin square (eight days, eight treatments and eight cycling heifers). The formulations were delivered in vaginal route and the injectable oxytocin was applied intravenously, all of them having 10 IU of oxytocin. Blood samples (n=7) were collected from each animal, the first at time 0, prior to the administration of the treatment, and the following every three minutes until 18 minutes. Oxytocin was extracted from plasma using the C18 Sep-Pak column and measured with the commercial kit Oxytocin EIA. The responses were evaluated using the nonparametric ANOVA and the Kruskal Wallis test was used to compare the means. Statistical difference was observed between times 0 and 12 (p<0,05) for the oxytocin plus glycerin formulation, showing that absorption did occur. Nonetheless, it does not suppress the need for further research before it can be effectively used in female bovine management.

Abstract Background Some peptides purified from the venom of the spider Phoneutria nigriventer have been identified as potential sources of drugs for pain treatment. In this study, we characterized the antinociceptive effect of the peptide PnPP-19 on the central nervous system and investigated the possible involvement of opioid and cannabinoid systems in its action mechanism. Methods Nociceptive threshold to thermal stimulation was measured according to the tail-flick test in Swiss mice. All drugs were administered by the intracerebroventricular route. Results PnPP-19 induced central antinociception in mice in the doses of 0.5 and 1 μg. The non-selective opioid receptor antagonist naloxone (2.5 and 5 μg), μ-opioid receptor antagonist clocinnamox (2 and 4 μg), δ-opioid receptor antagonist naltrindole (6 and 12 μg) and CB1 receptor antagonist AM251 (2 and 4 μg) partially inhibited the antinociceptive effect of PnPP-19 (1 μg). Additionally, the anandamide amidase inhibitor MAFP (0.2 μg), the anandamide uptake inhibitor VDM11 (4 μg) and the aminopeptidase inhibitor bestatin (20 μg) significantly enhanced the antinociception induced by a low dose of PnPP-19 (0.5 μg). In contrast, the κ-opioid receptor antagonist nor-binaltorphimine (10 μg and 20 μg) and the CB2 receptor antagonist AM630 (2 and 4 μg) do not appear to be involved in this effect. Conclusions PnPP-19-induced central antinociception involves the activation of CB1 cannabinoid, μ- and δ-opioid receptors. Mobilization of endogenous opioids and cannabinoids might be required for the activation of those receptors, since inhibitors of endogenous substances potentiate the effect of PnPP-19. Our results contribute to elucidating the action of the peptide PnPP-19 in the antinociceptive pathway.